Figure 4. Co-occurring KMT2D and TP53... | American Society of Hematology

$Co-occurring KMT2D and TP53 mutations are prevalent and adversely prognostic in human DLBCL. (A) Proportion of Trp53 alterations in murine sgKmt2d-targeted B-cell lymphoma (n = 12) and others (n = 92). Fisher exact test. (B) Number of co-occurring combinations of driver alterations in 489 untreated patients with DLBCL from National Cancer Institute's Center for Cancer Research (NCICCR) cohort. (C) HRs with 95% CIs for overall survival evaluated by Cox proportional hazards model incorporating presence of KMT2D, TP53, or both mutations, IPI, and genetic subtype according to the LymphGen classification in 230 untreated patients with DLBCL from NCICCR cohort. (D) Proportion of KMT2D, TP53, or both mutations in 489 untreated and 117 patients with relapsed/refractory DLBCL. (E) Number of co-occurring combinations of driver mutations in 117 patients with relapsed/refractory DLBCL. In panels B,E, genetic subtype related to each altered gene is shown according to the LymphGen classification. Bars are colored by odds ratios calculated by Fisher exact test. Aberrant somatic hypermutation target genes are removed. CI, confidence interval; HR, hazard ratio; IPI, International Prognostic Index; re, rearrangement.$

Figure 4.

Co-occurring KMT2D and TP53 mutations are prevalent and adversely prognostic in human DLBCL. (A) Proportion of Trp53 alterations in murine sgKmt2d-targeted B-cell lymphoma (n = 12) and others (n = 92). Fisher exact test. (B) Number of co-occurring combinations of driver alterations in 489 untreated patients with DLBCL from National Cancer Institute's Center for Cancer Research (NCICCR) cohort. (C) HRs with 95% CIs for overall survival evaluated by Cox proportional hazards model incorporating presence of KMT2D, TP53, or both mutations, IPI, and genetic subtype according to the LymphGen classification in 230 untreated patients with DLBCL from NCICCR cohort. (D) Proportion of KMT2D, TP53, or both mutations in 489 untreated and 117 patients with relapsed/refractory DLBCL. (E) Number of co-occurring combinations of driver mutations in 117 patients with relapsed/refractory DLBCL. In panels B,E, genetic subtype related to each altered gene is shown according to the LymphGen classification. Bars are colored by odds ratios calculated by Fisher exact test. Aberrant somatic hypermutation target genes are removed. CI, confidence interval; HR, hazard ratio; IPI, International Prognostic Index; re, rearrangement.

This Feature Is Available To Subscribers Only